StockNews.com upgraded shares of Abbott Laboratories (NYSE:ABT – Free Report) from a buy rating to a strong-buy rating in a ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q4 CY2024, with sales up 7.2% year on year to $10.97 ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

Abbott Laboratories (NYSE:ABT) is a healthcare products provider that operates through medical devices, established pharmaceutical products, and other segments. The company’s Q3 performance was good ...

and is promoted as the next stage in child nutrition – all in an attempt to convince parents and caregivers to buy a product toddlers don’t need.” Abbott Laboratories is purposefully ...

Shares of Abbott India surged 5.60% higher at ₹27,605.45 on the BSE on Tuesday. The pharma stock reacted positively to the ...

The company's Q3 profit increased 16 per cent year-on-year (Y-o-Y) to Rs 360.78 crore as compared to Rs 310.98 crore ...